Drugs in R & D

, Volume 4, Issue 2, pp 103–109 | Cite as

Evaluation of the Antiretroviral Activity of a New Polyherbal Drug (Immu-25) in Patients with HIV Infection

  • P. R. Usha
  • M. U. R. Naidu
  • Y. S. N. Raju
Original Research Article


Objective: To evaluate the clinical efficacy and safety of a new polyherbal preparation, Immu-25, in HIV-infected patients.

Methods: 36 patients (10 female, 26 male) with a mean age of 35 ± 10 years, with confirmed HIV infection with a CD4 count <500 cells/μL, received two capsules of the test drug twice daily for 18 months in this open-label pilot study. Patients were evaluated at monthly intervals for general signs and symptoms, development of opportunistic infections, and changes in weight and performance index. Lymphocyte phenotyping and routine haematological, biochemical, hepatic and renal parameters were recorded after every 6 months of drug therapy. Viral load was evaluated before and after every 6 months of treatment.

Results: The polyherbal test preparation produced good symptomatic improvement within 6 months. There was an increase in mean (95% CI) weight from 58 (53–64)kg to 63 (56–69)kg, 64 (58–72)kg and 68 (62–74)kg after 6, 12 and 18 months of treatment, respectively. The incidence and severity of symptoms such as diarrhoea, fatigue, anorexia, cough and fever decreased with drug treatment. There was a decrease in the mean (95% CI) viral load from 326 438 (428 600–186 420) copies/mL to 180 495 (258 300–124 000) copies/mL and 22 069 (42 100–16 000) copies/mL after 6 and 12 months of treatment, respectively. The decrease in viral load was associated with an increase in mean (95% CI) CD4 count from a baseline of 243 (203–388) cells/μL to 336 (263–486) cells/μL after 6 months of therapy, and this continued to rise to 527 (285–767) cells/μL (p < 0.001) and 618 (362–1012) cells/μL (p < 0.001) after 12 and 18 months of treatment, respectively. With the exception of mild gastrointestinal adverse effects, the drug was well tolerated. Both patients and investigators rated the treatment as good or very good.

Conclusion: The polyherbal drug Immu-25 showed a favourable effect in patients with HIV infection. The test drug decreased the mean viral load, which was associated with good symptomatic improvement and an increase in the mean CD4 cell count. On the basis of these data, it can be concluded that this herbal drug may have a good immunomodulatory effect and has potential as a co-therapeutic agent in the management of HIV infection. Further studies are warranted to confirm its therapeutic potential.


Viral Load Test Drug Case Record Form Oral Thrush Lymphocyte Phenotyping 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank Indian Herbs Pvt. Ltd. Saharanpur, U.P. India for providing the test drug and research material, and for a research grant for conducting the present study.


  1. 1.
    Weniger BC, Brown T. The march of AIDS through Asia. N Engl J Med 1996; 335: 343–5PubMedCrossRefGoogle Scholar
  2. 2.
    Vermani K, Garg S. Herbal medicines for sexually transmitted diseases and AIDS. J Ethnopharmacol 2002 Apr; 80 (1): 49–66PubMedCrossRefGoogle Scholar
  3. 3.
    Wu JA, Attele AS, Zhang L, et al. Anti-HIV activity of medicinal herbs: usage and potential development. Am J Chin Med 2001; 29 (1): 69–81PubMedCrossRefGoogle Scholar
  4. 4.
    Sharma DN, Khosa RL. Immunomodulators of plant origin: a review. Anc Sci Life 1994; 13: 326–9Google Scholar
  5. 5.
    Bianchi A, Adamoli R, Durante A, et al. The clinical research on medicinal plants used in HIV infection: a bibliographic search. Abstract presented as poster no. 42393 at XII World AIDS Conference at Geneva; 1998Google Scholar
  6. 6.
    Lu WB, Wen RX, Guan CF. A report on 8 seronegative converted HIV/AIDS patients with traditional Chinese medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 1997 May; 17 (5): 271–3PubMedGoogle Scholar
  7. 7.
    Durant J, Gozalez G, Vandermander J, et al. Efficacy and safety of Buxus sempervirens L. preparation (SPV30) in HIV-infected asymptomatic patients: a multicentre, randomised, double-blind, placebo-controlled trial. Phytomedicine 1998; 5: 1–10PubMedCrossRefGoogle Scholar
  8. 8.
    Chatterjee S, Das SN. Immunopotentiation by IMMU-21 in immunocompromised rats. Ani Sci Life 1997; 16: 200–5Google Scholar
  9. 9.
    Chatterjee S, Das SN. Effect of IMMU-21 on murine peritoneal macrophages and splenic lymphocytes. Ani Sci Life 1996; 15 (4): 250–3Google Scholar
  10. 10.
    Pande CB, VijayKumar LA. A study on the immunomodulating action of ZEETRESS. Poult Adv 1994; 27: 53–5Google Scholar
  11. 11.
    Karnofsky D, Burchenal JH. Clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949: 199–205Google Scholar
  12. 12.
    Thatte UM, Dahanukar SA. Immunotherapeutic modification of experimental infection by Indian medicinal plants. Phytother Res 1989; 3: 43–9CrossRefGoogle Scholar
  13. 13.
    Usha PR, Naidu MUR, Vijay T, et al. Clinical evaluation of efficacy and safety of a new polyherbal drug in the management of HIV infection [abstract]. Published Proceedings of 8th International Congress on Infectious disease 1998; p. 146Google Scholar
  14. 14.
    Ghosal S, Lal J, Srivastava R, et al. Immunomodulatory and CNS effects of sitoindosides IX and X, two new glycowithanolides from Withania somnifera. Phytother Res 1989; 3: 201–4CrossRefGoogle Scholar
  15. 15.
    Dahnukar SS, Thatte UM, Rege NN, et al. Immunotherapeutic modification of diverse experimental infections by Tinospora cordifolia, Asparagus and Withania somnifera. Ind J Pharmacol 1989; 21: 53–5Google Scholar
  16. 16.
    Dahnukar SS, Thatte UM, Rege NN et al. Immunotherapeutic modification of diverse experimental infections by Tinospora cordifolia, asparagus and Withania somnifera. Ind J Pharmacol 1989; 21: 53–5.Google Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  • P. R. Usha
    • 1
  • M. U. R. Naidu
    • 1
  • Y. S. N. Raju
    • 2
  1. 1.Department of Clinical Pharmacology, and TherapeuticsNizam’s Institute of Medical SciencesHyderabadIndia
  2. 2.Department of General MedicineNizam’s Institute of Medical SciencesHyderabadIndia

Personalised recommendations